Company profile
Arrowhead Pharmaceuticals
RNAi therapeutics
Share price · ARWR
$87.90+13.95 (+18.86%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(8 total)
8Total Assets
0Approved
3Phase 3 / Filed
5Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
ARO-HSDNo recent activity | Phase 3 | HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) mRNA | MASH / NASH |
Plozasiran(Redemplo) | Phase 3 | APOC3RNA / oligonucleotide | Atherosclerotic Cardiovascular Disease |
| Phase 3 | ANGPTL3 gene mRNA (hepatic)RNA / oligonucleotide | Atherosclerotic Cardiovascular Disease | |
| Phase 2 | RNAi (metabolic/obesity pathway)RNA / oligonucleotide | Obesity | |
| Phase 2 | PCSK9/APOC3RNA / oligonucleotide | Atherosclerotic Cardiovascular Disease | |
| Phase 2 | RNAi (metabolic/obesity pathway)RNA / oligonucleotide | Obesity | |
| Phase 2 | MAPT mRNA (RNAi/ASO)RNA / oligonucleotide | Alzheimer's Disease | |
| Phase 2 | RAGE (receptor for advanced glycation end-products)RNA / oligonucleotide | Asthma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.